Stocks and Finance

Medivation

Medivation 5/21/2012

19:09 : Medivation and Astellas Announce Submission of New Drug Application for ... - SAN FRANCISCO, CA and TOKYO--(Marketwire - May 21, 2012) - Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced that Medivation has submitted a New Drug Application (NDA) to the U.S. Food and ...
Source : marketwire-com

Medivation 5/18/2012

06:37 : Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data ... - SAN FRANCISCO, CA and TOKYO--(Marketwire - May 18, 2012) - Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that six abstracts related to enzalutamide (formerly MDV3100) will be presented at the upcoming American ...
Source : marketwire-com

Medivation 3/13/2012

22:57 : Medivation, Inc. Prices $225 Million 2.625% Convertible Senior Notes Due ... - SAN FRANCISCO, CA--(Marketwire - Mar 13, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced the pricing of its offering of $225 million aggregate principal amount of 2.625% convertible senior notes due April 1, 2017 registered under ...
Source : marketwire-com

Medivation 3/12/2012

16:34 : Sniffing out investments, Medivation to sell $175M in notes - Medivation Inc. hopes to raise about $175 million through a convertible senior note offering. The San Francisco-based drug developer (NASDAQ: MDVN), whose stock has shot up more than 300 percent since it disclosed results of a successful ...
Source : bizjournals-com
15:19 : Medivation, Inc. to Offer $175 Million Convertible Senior Notes Due 2017 - SAN FRANCISCO, CA--(Marketwire - Mar 12, 2012) - Medivation, Inc.(NASDAQ: MDVN) today announced its intention to offer, subject to market and other conditions, approximately $175 million principal amount of convertible senior notes due ...
Source : marketwire-com

Medivation 2/1/2012

13:25 : Medivation rockets 24% on drug study - BOSTON (MarketWatch) -- Shares of Medivation Inc. rocketed 24% to $68.69 on Wednesday, the day after it released positive Phase III clinical results for its prostate cancer therapy MDV3100. The study showed that men taking MDV3100 lived, ...
Source : marketwatch-com
08:32 : Medivation (MDVN) +20% premarket after the company and its partner Astella - Medivation (MDVN) +20% premarket after the company and its partner Astellas announce positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously ...
Source : seekingalpha-com

Medivation 1/17/2012

19:04 : Summary Box: Pfizer, Medivation end drug's testing - STRIKE OUT: An experimental Alzheimer's drug doctors hoped would be the first to stop or even reverse the course of the mind-robbing disease failed in a third study, dashing hopes....
Source : usnews-com
07:42 : Pfizer, Medivation end drug development deal - NEW YORK (AP) -- Drug developers Pfizer and Medivation are ending the development of a potential Alzheimer's disease treatment after the drug yielded disappointing results in a late-stage clinical study....
Source : usnews-com
07:40 : Medivation (MDVN) and Pfizer (PFE) announce that their jointly-developed ... - Medivation (MDVN) and Pfizer (PFE) announce that their jointly-developed Dimebon treatment of Alzheimer's failed to achieve statistically significant results for endpoints in a Phase III trial. Due to the development, the ...
Source : seekingalpha-com
07:38 : Medivation, Pfizer end efforts on Alzheimer's drug - TEL AVIV (MarketWatch) -- Medivation Inc., the San Francisco biopharma firm, and Pfizer Inc., the New York health-care major, said Tuesday that dimebon, a drug they evaluated to treat Alzheimer's disease, didn't produce ...
Source : marketwatch-com

Medivation 12/26/2011

16:33 : Medivation Announces Participation at Upcoming Investor Conference - SAN FRANCISCO, CA--(Marketwire - Dec 26, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following investor conference:
Source : marketwire-com

Medivation 11/3/2011

11:40 : Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN) - New technology usually comes with its share of consumer concerns. It's no surprise that urban legends and myths have proliferated about the new EMV chip credit cards. Here are a few of the most common, along with our expert opinion as to their veracity:
Source : 247wallst-com

Medivation 7/13/2011

07:03 : Medivation Names Stewart Hallett Vice President of Clinical Operations - SAN FRANCISCO, CA--(Marketwire - Jul 13, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that Stewart Hallett, MBA, has been promoted to vice president, clinical operations. He takes the position with nearly 20 years of biopharmaceutical ...
Source : marketwire-com
actualidad Medivation -


Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts